Data Insights

TG-4050 by Transgene for Oral Cavity (Mouth) Cancer: Likelihood of Approval

TG-4050 is under clinical development by Transgene and currently in Phase II for Oral Cavity (Mouth) Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - TG-4050 in Oral Cavity (Mouth) Cancer

Data Insights

TG-4050 by Transgene for Oropharyngeal Cancer: Likelihood of Approval

TG-4050 is under clinical development by Transgene and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - TG-4050 in Oropharyngeal Cancer

Data Insights

TG-4050 by Transgene for Laryngeal Cancer: Likelihood of Approval

TG-4050 is under clinical development by Transgene and currently in Phase II for Laryngeal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - TG-4050 in Laryngeal Cancer

Data Insights

TG-4050 by Transgene for Hypopharyngeal Cancer: Likelihood of Approval

TG-4050 is under clinical development by Transgene and currently in Phase II for Hypopharyngeal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - TG-4050 in Hypopharyngeal Cancer

Data Insights

TG-4050 by Transgene for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

TG-4050 is under clinical development by Transgene and currently in Phase II for Head And Neck Squamous Cell Carcinoma (HNSC)....

Likelihood of Approval and Phase Transition Success Rate Model - TG-4050 in Head And Neck Squamous Cell Carcinoma (HNSC)

Data Insights

Tipapkinogene sovacivec by Transgene for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

Tipapkinogene sovacivec is under clinical development by Transgene and currently in Phase II for Head And Neck Squamous Cell Carcinoma...

Data Insights

Tipapkinogene sovacivec by Transgene for Oropharyngeal Cancer: Likelihood of Approval

Tipapkinogene sovacivec is under clinical development by Transgene and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase...